Patents by Inventor Rajinder Singh

Rajinder Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tyrosine kinase inhibitors
    Patent number: 10130623
    Abstract: Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: November 20, 2018
    Assignee: RIGEL PHARMACEUTICALS, INC.
    Inventors: Sacha Holland, Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Rao Kolluri, Ihab Darwish, Esteban Masuda, Jiaxin Yu
  • MANTLE PHENOTYPE DETECTION IN PALM
    Publication number: 20180314794
    Abstract: Methods, compositions, kits, and computer program code are provided for predicting somaclonal abnormality (e.g., a Mantled phenotype) in a plant and or sorting plants based on the predicted presence or absence of somaclonal abnormality.
    Type: Application
    Filed: April 25, 2018
    Publication date: November 1, 2018
    Inventors: Meilina Ong Abdullah, Ooi Siew Eng, Leslie Low Eng Ti, Rajinder Singh, Rajanaidu Nookiah, Ravigadevi Sambanthamurthi, Nan Jiang, Steven W. Smith, Nathan D. Lakey, Rob Martienssen, Jared Ordway, Michael Hogan
  • SYSTEM, METHOD AND COMPUTER-ACCESSIBLE FOR CATHETER-BASED OPTICAL DETERMINATION OF MET-MYOGLBIN CONTENT FOR ESTIMATING RADIOFREQUENCY ABLATED, CHRONIC LESION FORMATIN IN TISSUE
    Publication number: 20180303544
    Abstract: An exemplary system, method and computer-accessible medium for determining a characteristic(s) of a tissue(s), can be provided which can include, for example, ablating the tissue(s), illuminating the tissue(s) during the ablation procedure; and continuously determining the characteristic(s) based on the ablation and illumination procedures. The tissue(s) can be ablated using radiofrequency ablation. The illumination procedure can be performed with a radiation in a visible spectrum.
    Type: Application
    Filed: September 12, 2016
    Publication date: October 25, 2018
    Inventors: Christine P. HENDON, Rajinder SINGH-MO
  • METHODS OF TREATING IBRUTINIB-RESISTANT DISEASE
    Publication number: 20180296579
    Abstract: Disclosed are methods of treating an ibrutinib-resistant disease in a mammal with a compound of Formula (I): wherein R is described herein. In certain embodiments, a compound of Formula (I) inhibits the activity of a variant Btk, providing a method of treating ibrutinib-resistant diseases, such as ibrutinib-resistant lymphoma.
    Type: Application
    Filed: April 18, 2016
    Publication date: October 18, 2018
    Inventors: Yasumichi Hitoshi, Nan Lin, Rajinder Singh
  • AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS
    Publication number: 20180273476
    Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Application
    Filed: January 22, 2018
    Publication date: September 27, 2018
    Inventors: Andrew Harvey, Agnes Bombrun, Rachel Cooke, Isabelle Jeanclaude-Etter, Nathan Kuchel, Jerome Molette, Jorgen Mould, Dharam Paul, Rajinder Singh, Cristina Donini, Veronique Colovray, Thomas Avery, Julia Crossman, Justin Ripper
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20180265503
    Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
    Type: Application
    Filed: May 24, 2018
    Publication date: September 20, 2018
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Yan Chen, Vanessa Taylor, Hui Li, Rajinder Singh
  • Nrf2 Activating Compounds and Uses Thereof
    Publication number: 20180258070
    Abstract: Aspects of the present disclosure include compounds that activate Nrf2. Such compounds may find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: November 13, 2017
    Publication date: September 13, 2018
    Inventors: Matthew Duncton, Rajinder Singh
  • Nrf2 Activating Compounds and Uses Thereof
    Publication number: 20180258063
    Abstract: Aspects of the present disclosure include compounds that activate Nrf2. Such compounds find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: November 13, 2017
    Publication date: September 13, 2018
    Inventors: Matthew Duncton, Rajinder Singh
  • Benzazole compounds and methods for making and using the compounds
    Patent number: 10065946
    Abstract: Disclosed are novel benzazole compounds and compositions comprising the compounds. The compounds are useful as kinase inhibitors including interleukin receptor associated kinases (IRAK) inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: September 4, 2018
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rose Yen, Yan Chen, Rajinder Singh, Vanessa Taylor
  • Process for the Preparation of Pharmaceutical Grade Ferric Citrate
    Publication number: 20180222836
    Abstract: A one-pot process is disclosed for the preparation of pharmaceutical grade ferric citrate that includes preparing a ferric hydroxide slurry followed by treatment with a citrate ion source to yield pharmaceutical grade ferric citrate.
    Type: Application
    Filed: August 4, 2016
    Publication date: August 9, 2018
    Inventors: Anurag Anil Smart, Yogesh Subhash Aher, Sunilkumar Vinubhai Gohel, Rajinder Singh Siyan, Nandu Baban Bhise, Girij Pal Singh
  • Ubiquitination inhibitors
    Patent number: 10040766
    Abstract: Disclosed are sulfonamidoquinoline compounds, as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, R2, R3 and R4 are as described herein. In certain embodiments, a compound disclosed herein inhibits ubiquitination, and can be used to treat disease by blocking the degradation of tumor suppressors.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: August 7, 2018
    Assignee: RIGEL PHARMACEUTICALS, INC.
    Inventors: David Carroll, Arvinder Sran, Rajinder Singh, Jianing Huang, Lyuben Tsvetkov, Sarkiz Issakani, Donald Payan, Simon Shaw
  • PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS
    Publication number: 20180208612
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Application
    Filed: March 22, 2018
    Publication date: July 26, 2018
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Ryan Kelley, Hui Li, Thilo Heckrodt, Yan Chen, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
  • PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS
    Publication number: 20180208613
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Application
    Filed: March 23, 2018
    Publication date: July 26, 2018
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Ryan Kelley, Hui Li, Thilo Heckrodt, Yan Chen, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
  • PROCESS FOR PREPARATION OF CYSTEAMINE BITARTRATE
    Publication number: 20180193292
    Abstract: The present invention provides process for preparation of cysteamine bitartrate comprising reacting cysteamine or its salt with tartaric acid. The present invention further provides crystalline form L1 of cysteamine bitartrate having characteristic diffraction peaks at 10.36, 14.54, 17.23, 18.03, 19.24, 20.76, 21.20, 22.02, 23.37, 23.64, 27.71, 28.28, 29.26, 31.33, 32.84, 33.83, 35.51, 36.74±0.2 degree two theta in an X-ray diffraction pattern and process for preparation thereof. The present invention provides crystalline form L2 of cysteamine bitartrate having characteristic diffraction peaks at 7.4, 10.3, 11.0, 11.4, 14.4, 14.9, 18.6, 19.4, 20.1, 20.8, 21.9, 22.3, 22.5, 23.5±0.2 degree two theta in an X-ray diffraction pattern and process for preparation thereof.
    Type: Application
    Filed: January 11, 2018
    Publication date: July 12, 2018
    Inventors: Pankaj Ramchandra CHAUDHARI, Sukhdeo Sampat GUNJAL, Raju Muktaji WALUNJ, Anurag TRIVEDI, Rajinder Singh SIYAN, Nandu Baban BHISE, Girij Pal SINGH
  • WIRELESS CONFIGURATION OF WIRELESS DISTRIBUTION SYSTEM (WDS) WI-FI RANGE EXTENDERS USING NON-WI-FI WIRELESS COMMUNICATION CHANNELS
    Publication number: 20180184283
    Abstract: A configuration server detects a network change and initiates a configuration process. A smartphone executing a mobile app communicates with the configuration server with a cellular data network transceiver (e.g., a 3G or 4G transceiver), and communicates with slave base stations with a Bluetooth transceiver (e.g., a BILE transceiver) or other one-to-many wireless channel. The configuration server also communicates over a wired connection with a master base station to synchronize WDS configuration data between the master and slave base stations. WDS configuration data is dynamically generated to prevent rogue devices from using preconfigured WDS configuration.
    Type: Application
    Filed: December 27, 2016
    Publication date: June 28, 2018
    Inventor: Rajinder SINGH
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 10005767
    Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: June 26, 2018
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Yan Chen, Vanessa Taylor, Hui Li, Rajinder Singh
  • Protein kinase C inhibitors and uses thereof
    Patent number: 10005777
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: June 26, 2018
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Matthew Duncton, Jing Zhang, Salvador Alvarez, Kin Tso, Sacha Holland, Rose Yen, Rao Kolluri, Thilo Heckrodt, Yan Chen, Esteban Masuda, Hui Li, Donald G. Payan, Ryan Kelley
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20180162848
    Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.
    Type: Application
    Filed: February 8, 2018
    Publication date: June 14, 2018
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Thilo J. Heckrodt, Yan Chen, Darren John McMurtrie, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen
  • MADS-BOX DOMAIN ALLELES FOR CONTROLLING SHELL PHENOTYPE IN PALM
    Publication number: 20180160639
    Abstract: Nucleic acid and polypeptide sequences for predicting and controlling shell phenotype in palm.
    Type: Application
    Filed: June 14, 2016
    Publication date: June 14, 2018
    Inventors: Rajinder Singh, Leslie Low Eng Ti, Leslie Ooi Cheng Li, Meilina Ong Abdullah, Rajanaidu Nookiah, Ravigadevi Sambanthamurthi, Andrew Van Brunt, Muhammad A. Budiman, Steven W. Smith, Nathan D. Lakey, Rob Martienssen, Jared Ordway
  • Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof
    Patent number: 9994518
    Abstract: Disclosed are compounds of Formula (IVA), or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof: Formula (IVA), wherein “RIa”, “RIb”, “RIc”, “RId”, “RIe”, are defined herein above, which compounds are believed suitable for use in positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR) receptors, for example, those found in the cerebral cortex and the hippocampus. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Alzheimer's disease (AD), schizophrenia, and Parkinson's disease (PD), or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: June 12, 2018
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Kenneth Leavitt, Brendan Crowley, Ian M. Bell, Andrew Harvey, Thomas Avery, Dharam Paul, Justin Ripper, Belinda Huff, Rajinder Singh, Laurent Schaeffer, Christophe Joseph, Christophe Morice, Bruno Giethlen, Patrick Bazzini, Aurelie Fromeyer